Analysts Set Acadia Healthcare Company, Inc. (ACHC) Price Target at $57.00
- Author: Zachary Reyes Feb 25, 2017,
Feb 25, 2017, 4:12
Returns and Valuations for Acadia Healthcare Company, Inc. The firm had revenue of $702.89 million for the quarter, compared to analyst estimates of $708.41 million. Over the past month the firm's stock is 9.75%, 11.70% for the last quarter, -17.16% for the past six-months and -21.32% for the a year ago. The companys revenue was up 53.1% compared to the same quarter past year. "(ACHC) to Post FY2016 Earnings of $2.43 Per Share, Craig Hallum Forecasts" was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and reposted in violation of USA and worldwide trademark and copyright law. Jefferies Group LLC reissued a "buy" rating on shares of Acadia Healthcare Company in a research report on Friday, December 2nd.
A number of other large investors have also recently modified their holdings of the company. The Stock has a 52-Week High of $42.49 and 52-Week Low of $17.02 following the dates, it touched its 52-Week High on Jun 9, 2016 and 52-Week Low on Mar 1, 2016.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, ACADIA Pharmaceuticals Inc. They set a "buy" rating and a $43.00 price objective on the stock.
Covering research analysts have taken a stance on where they see ACADIA Pharmaceuticals Inc. (NASDAQ:ACHC), 10 rate it "Buy", 4 "Outperform", 2 "Underperform", 0 "Sell", while 0 "Hold". ACADIA Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $41.25.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) last ended at $39.56, sending the company's market cap near $4.79B.
Company has reported several Insider transactions to the SEC, on Feb 7, 2017, Scott Schwieger (Chief Compliance Officer) sold 5,126 shares at 52.02 per share price.On Dec 16, 2016, Reeve B Waud (director) sold 28,000 shares at 34.35 per share price.On Aug 17, 2016, David M. Duckworth (Chief Financial Officer) sold 16,670 shares at 54.33 per share price. Calvert Investment Management Inc. raised its stake in Acadia Healthcare Company by 0.9% in the second quarter. In the final minutes of trading on Thursday, shares hit $43.24, a fall of 23 percent in the last 12 months. The Predicted Move on the 7th day after ACADIA Pharmaceuticals Inc. The Closing Price of the stock before earnings was $27.05 while on the Next day the stock closed its trading session at $27.65 with a percentage change of 2.22% from the price of 27.05 before Earnings. Legal & General Group Plc now owns 5,366 shares of the company's stock valued at $297,000 after buying an additional 302 shares during the last quarter.
In other news, EVP Terrence O. Moore sold 157,540 shares of the business's stock in a transaction dated Thursday, February 16th. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Following the completion of the sale, the director now directly owns 55,673 shares in the company, valued at $1,992,536.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. A significant increase in trading volume means that more than double the average amount of stocks are moving. Putnam Investments LLC now owns 16,647 shares of the biopharmaceutical company's stock valued at $480,000 after buying an additional 286 shares during the period. The disclosure for this sale can be found here. Wells Fargo & Company MN now owns 6,857,782 shares of the company's stock worth $339,803,000 after buying an additional 1,581,959 shares in the last quarter. Corporate insiders own 21.65% of the company's stock.